The role of RAS modulation after stroke has been investigated by our group, and others, and investigations have demonstrated that Compound 21 (C21), the first selective non-peptide angiotensin II type 2 receptor agonist, provides a neurovascular protective effect and enhances sustained functional improvement at seven days after stroke. The gene discussed is AGTR2; the disease is stroke disorder.